Adrianne R. Wilson‐poe

Legacy Health

2 papers in the library · 15 citations · publishing 2024

Papers

Developing the Open Psychedelic Evaluation Nexus consensus measures for assessment of supervised psilocybin services: An e-Delphi study

Journal of Psychopharmacology June 18, 2024 Kim Hoffman, Alissa Bazinet, Kellie Pertl et al. 14 citations

Experts with extensive experience facilitating psilocybin experiences, including in ceremonial settings, indigenous practices, and clinical trials, developed a set of core measures to monitor the safety, quality, and outcomes of supervised psilocybin services. Through a three-phase e-Delphi process with 36 experts, 55 candidate measures were identified and then prioritized to a core set of 11 process measures (e.g., preparatory hours with client, documentation of touch/sexual boundaries), 11 outcome measures (e.g., adverse events, well-being), and 17 structure measures (e.g., facilitator training in trauma informed care). The findings suggest that service providers and policy makers should consider standardizing these measures for community-based psilocybin services.

DOI: 10.1177/02698811241257839 Psilocybin Delphi method Thematic analysis Applied psychology +4

Commentary on Darkeet al.: Expanded psychedelic access requires new safety monitoring systems

Addiction June 17, 2024 P. Todd Korthuis, Adrianne R. Wilson‐poe, Joshua C. Black et al. 1 citation

As psychedelic use expands, adverse effects will increase proportionally. Darke et al. characterized 33 LSD and 10 psilocybin-related deaths in Australia between 2000 and 2023, finding that traumatic accidents and physical self-harm in private settings accounted for most deaths. The 43 deaths over 24 years are rare compared to the more than 325,000 Australians who reported using hallucinogens in 2019 alone. Co-use of other substances was common: 75% of LSD cases and 80% of psilocybin cases involved other substances. The findings suggest regulated services must consider harm reduction, including skilled supervision, screening for comorbidities, and counseling against other drug use. Better population-level monitoring frameworks are urgently needed as legal frameworks for psychedelic services expand.

DOI: 10.1111/add.16589 Psychology Medicine